BXP vs DOC
BXP, Inc. vs Healthpeak Properties — AI-powered side-by-side comparison
VS
DOC
Healthpeak Properties
64
Buy
| Metric | BXP | DOC |
|---|
| AI Score |
63
|
64
|
| Price |
$67.44
|
$20.50
|
| P/E Ratio |
36.09×
|
58.60×
|
| ROE |
5.4%
|
1.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
46.8%
|
2.5%
|
| Debt / Equity |
3.17×
|
1.32×
|
| Dividend Yield |
4.1%
|
5.9%
|
| RSI (14) |
39.1
|
31.1
|
| Beta |
1.039
|
0.991
|
| Expected Upside |
+2.9%
|
+1.6%
|
AI Committee View
Current Innellis committee reasoning for BXP versus DOC.
DOC leads by 1 points.
DOC scores 64/100 (Buy) versus BXP at 63/100 (Buy).
BXP Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Dividend yield of 4.1% pays you to wait — Value
- EPS growing 6713.9% YoY — Growth
- 3 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 36.2 is moderate-to-rich — Value
- Debt-to-equity of 3.30 adds balance-sheet risk to the value case — Value
- MACD histogram negative -- bearish momentum — Technical
DOC Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Price trading below the lower Bollinger Band -- stretched to the downside — Technical